Latest CA 125 Test Companies Update
Abbott Laboratories Launched their ARCHITECT® i1000SR System with a new CA 125 assay offering improved sensitivity and faster turnaround time.Focused on providing integrated laboratory solutions for early cancer detection and disease management.
Roche Diagnostics Introduced their Elecsys® CA 125 II immunoassay on cobas e 801 analyzer, offering high analytical performance and automation in cancer diagnosis workflows.Collaborated with healthcare providers to implement standardized CA 125 testing protocols for optimal clinical utility.
Siemens Healthineers Launched their Atellica® CH 930 analyzer with a fully automated CA 125 assay, improving efficiency and workflow in high-volume laboratories.Emphasized their commitment to providing reliable and scalable diagnostic solutions for cancer screening and monitoring.
Bio-Rad Laboratories Introduced their QMS™ Gilus CA 125 II assay on their automated immunoassay platform, offering simplified workflows and rapid reporting of test results.Focused on providing cost-effective and accessible solutions for clinical labs in resource-constrained settings.
Randox Laboratories Developed a point-of-care rapid test for CA 125, enabling faster diagnosis and potentially facilitating early intervention in resource-limited environments.Partnered with healthcare organizations to pilot the use of their point-of-care test in remote clinics and community settings.
List of CA 125 Test companies in the market
- Allergan plc.
- Amgen Inc.
- Bayer
- BD
- Eli Lilly Company
- Merck & Co. Inc.
- Pfizer Inc.
- Teva Pharmaceuticals Private Limited
- AMAG Pharmaceuticals
- Johnson & Johnson
- Sanofi
- Novartis
- AbbVie Inc.
- GlaxoSmithKline plc.
